TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00980655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23vPS
Description: 0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
Study: NCT02432833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENVARSUS®
Description: Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROGRAF®
Description: Prograf® hard capsules, twice daily, oral formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAGRAF®
Description: Advagraf® prolonged-release hard capsules, once daily, oral formulation
Study: NCT01814215

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Keys to Healthy Family Child Care Homes
Description: The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
Study: NCT03435731

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dual Therapy
Description: Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
Study: NCT01649154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus
Study: NCT00795223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and bupivacaine
Description: 0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal morphine and marcaine
Description: 0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and bupivacaine
Description: 0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine and bupivacaine
Description: 0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
Study: NCT02313389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Methotrexate, Temozolomide
Description: Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
Study: NCT02526498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo APBI using HDR brachytherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03376750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO - OP
Description: CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO - OP
Description: CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
Study: NCT02180750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Work Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Pediatric clinic, ART
Study: NCT01814215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keys to Healthy Family Child Care Homes
Description: The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
Study: NCT02185456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository
Description: The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository
Description: The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: oral metronidazole 500 mg twice a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: oral metronidazole 500 mg twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: oral metronidazole 500 mg twice a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: oral metronidazole 500 mg twice a day for 7 days
Study: NCT00255164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
Study: NCT01647542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-875 Placebo
Description: TAK-875 placebo-matching tablets
Study: NCT04684433

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT02117986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colistin
Description: One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin
Description: One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
Study: NCT01255956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin eluting stent implantation
Description: Rapamycin eluting stent implantation for in-stent restenosis treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting balloon catheter
Description: Paclitaxel eluting balloon catheter for in-stent restenosis treatment
Study: NCT03993210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Fingerprinting (MRF)
Description: In MRF, multiple tissue properties are acquired simultaneously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Fingerprinting (MRF)
Description: In MRF, multiple tissue properties are acquired simultaneously.
Study: NCT00255164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study: NCT02404129

Intervention type: OTHER
Group type: OTHER
Intervention: Turn 180 test
Description: The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor.

Intervention type: OTHER
Group type: OTHER
Intervention: Turn 180 test
Description: The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor.

Intervention type: OTHER
Group type: OTHER
Intervention: Turn 180 test
Description: The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor.
Study: NCT03430856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Tregopil
Description: Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Tregopil
Description: Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
Study: NCT03581916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-JNJ-64326067
Description: 18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
Study: NCT03993210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-space Trajectory Imaging (QTI)
Description: By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-space Trajectory Imaging (QTI)
Description: By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging Machine (MRI)
Description: MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging Machine (MRI)
Description: MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
Study: NCT01167452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole/trimethoprim
Description: 2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
Study: NCT03369873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance Manual
Description: The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
Study: NCT03831919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNC III
Description: Hoya SYNC III design spectacle lenses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: single vision lenses
Description: single vision spectacle lenses with no addition
Study: NCT02521597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellscope
Description: The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional otoscope
Description: Use of a regular otoscope
Study: NCT02482753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg, administered orally twice per week (BIW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg, administered orally twice per week (BIW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg, PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg, PO daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: 25 mg, PO daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered orally twice per week (BIW)
Study: NCT01218971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 190 mg
Description: naltrexone for extended-release injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: naltrexone for extended-release injectable suspension
Study: NCT01613079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F
Description: Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F
Description: Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
Study: NCT04003623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib administered orally once daily.
Study: NCT03944278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Laser
Description: Thulium laser for skin resurfacing procedures
Study: NCT01673087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metyrapone
Description: 750 mcg, oral, administered twice, 3.5 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortrosyn
Description: 250 mcg, IV, bolus, in the afternoon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin ovine triflutate
Description: 100 mcg, IV, over 30 seconds, in the afternoon.
Study: NCT01371825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (SBC-102)
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
Study: NCT02963675

Intervention type: OTHER
Description: external unexposed reference group

Intervention type: OTHER
Description: external unexposed reference group
Study: NCT03680352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime/AAI101
Description: Fixed dose combination of cefepime and AAI101
Study: NCT01120873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamin 3D
Description: Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
Study: NCT03802734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindful meditation phone app
Description: Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
Study: NCT01583504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection of steroid and local anaesthetic
Description: 2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection of steroid and local anaesthetic
Description: 2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High volume saline injection
Description: After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise programme
Description: a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise programme
Description: a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
Study: NCT03002298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DMD gesture task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DMD button-press task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group gesture task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group button-press task
Description: Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
Study: NCT01391637

Intervention type: BIOLOGICAL
Intervention: HuCNS-SC transplant in the lead-in phase
Description: Long-term safety follow-up study
Study: NCT00905320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metallic Fasteners and Sutures
Description: Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metallic Fasteners Alone
Description: Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
Study: NCT00445835

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds
Description: A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative arm
Description: Conservative medical approach